|
1) Bankir I. Antidiuretic action of vasopressin: quantinative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res. 2001; 51: 372-90
|
|
|
|
2) Lee CR, Warkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003; 146: 9-18
|
|
|
|
|
|
3) Jard S. Mechanisms of action of vasopressin and vasopressin antagonist. Kidney Int Suppl. 1988; 26: 538-42
|
|
|
|
|
|
4) Xu YJ, Gopalakrishman V. Vasopressin increases cytosolic free [Ca2＋] in the neonatal rat car-diomyocyte. Evidence for V1 subtype receptors. Cir Res. 1991; 69: 239-45
|
|
|
|
|
|
5) Nielsen S, Chou CL, Marples D, et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci U S A. 1995; 92: 1013-7
|
|
|
|
|
|
6) Kalra PR, Anker SD, Coats AJ. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res. 2001; 51: 495-509
|
|
|
|
|
|
7) Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A subtype of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990; 82: 1724-9
|
|
|
|
|
|
8) Isnard R, Pousset F, Trochu J, et al. Prognostic value of neurohormonal activation and cardio-pulmonary exercise testing in patients with chro-nic heart failure. Am J Cardiol. 2000; 86: 417-21
|
|
|
|
|
|
9) Gheorgghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med. 2007; 167: 1998-2005
|
|
|
|
|
|
10) Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with sympto-matic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008; 52: 1540-5
|
|
|
|
|
|
11) Paterna S, Di Pasquale P, Parrinello G, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilatation and function in patients with heart failure and systolic dys-function. J Am Coll Cardiol. 2007; 49: 2151-9
|
|
|
|
|
|
12) Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral V2-receptor antago-nist, for hyponatremia. N Engl J Med. 2006; 355: 2099-112
|
|
|
|
|
|
13) Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: result from a double-blind, randomized trial. Circulation. 2003; 107: 2690-6
|
|
|
|
|
|
14) Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007; 9: 1064-9
|
|
|
|
|
|
15) Miyazaki T, Fujiki H, Yamamura Y, et al. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist-pharmacology and clinical trials. Cardiovasc Drug Rev. 2007; 25: 1-13
|
|
|
|
|
|
16) Gheorghiade M, Gattis WA, OConnor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004; 291: 1963-71
|
|
|
|
|
|
17) Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007; 297: 1332-43
|
|
|
|
|
|
18) Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007; 297: 1319-31
|
|
|
|
|
|
19) Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003; 107: 2690-6
|
|
|
|
|
|
20) Tahara A, Tomura Y, Wada K, et al. Effect of YM087, a potent nonpeptide vasopressin antago-nist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res. 1998; 38: 198-205
|
|
|
|
|
|
21) Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilatation and function in patients with heart failure and systolic dysfun-ction. J Am Coll Cardiol. 2007; 49: 2151-9
|
|
|
|
|